KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Treasury Shares (2018 - 2025)

Pacific Biosciences Of California (PACB) has 8 years of Treasury Shares data on record, last reported at $392000.0 in Q4 2025.

  • For Q4 2025, Treasury Shares changed 0.0% year-over-year to $392000.0; the TTM value through Dec 2025 reached $392000.0, changed 0.0%, while the annual FY2025 figure was $392000.0, 0.0% changed from the prior year.
  • Treasury Shares reached $392000.0 in Q4 2025 per PACB's latest filing, down from $18.1 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $18.1 million in Q3 2025 and bottomed at $8392.0 in Q2 2022.
  • Average Treasury Shares over 5 years is $6.4 million, with a median of $6.8 million recorded in 2021.
  • Peak YoY movement for Treasury Shares: tumbled 99.88% in 2022, then skyrocketed 150555.39% in 2023.
  • A 5-year view of Treasury Shares shows it stood at $7.4 million in 2021, then rose by 15.46% to $8.5 million in 2022, then surged by 32.49% to $11.3 million in 2023, then tumbled by 96.53% to $392000.0 in 2024, then changed by 0.0% to $392000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $392000.0 in Q4 2025, $18.1 million in Q3 2025, and $392000.0 in Q2 2025.